» Articles » PMID: 31172724

Protease-Activated Receptors 2-Antagonist Suppresses Asthma by Inhibiting Reactive Oxygen Species-Thymic Stromal Lymphopoietin Inflammation and Epithelial Tight Junction Degradation

Overview
Date 2019 Jun 8
PMID 31172724
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Protease-activated receptor 2 (PAR2) reportedly triggers the immune response in allergic asthma. We aimed to investigate the mechanism on allergic inflammation mediated by PAR2.

Methods: Human lung epithelial cells (A549 cells) were used for , and the German cockroach extract (GCE)-induced mouse model was developed for studies.

Results: In A549 cells, the levels of reactive oxygen species (ROS) and thymic stromal lymphopoietin (TSLP) were significantly increased by GCE treatment, but were suppressed by PAR2-antagonist (PAR2-ant) or N-acetylcysteine (NAC) treatment. Claudin-1 was degraded by GCE, and was restored by PAR2-ant or NAC in the cells. In the mouse model, the clinical appearance including bronchial hyperresponsiveness, bronchoalveolar lavage fluid analysis and total immunoglobulin E were significantly suppressed by PAR2-ant or NAC. Moreover, TSLP levels in the lung were suppressed by the same treatments in the lung. Claudin-1 was also degraded by GCE, and was restored by PAR2-ant or NAC.

Conclusions: ROS generation and epidermal tight junction degradation are triggered by protease, followed by the induction of TSLP in allergic asthma. Our findings could suggest that PAR2-ant or anti-oxidants could be considered for allergic diseases as preventive alternatives.

Citing Articles

Integrated Multi-Omics Analysis Reveals Mountain-Cultivated Ginseng Ameliorates Cold-Stimulated Steroid-Resistant Asthma by Regulating Interactions among Microbiota, Genes, and Metabolites.

Tang D, Wang C, Liu H, Wu J, Tan L, Liu S Int J Mol Sci. 2024; 25(16).

PMID: 39201796 PMC: 11354367. DOI: 10.3390/ijms25169110.


Par2-mediated responses in inflammation and regeneration: choosing between repair and damage.

Reches G, Piran R Inflamm Regen. 2024; 44(1):26.

PMID: 38816842 PMC: 11138036. DOI: 10.1186/s41232-024-00338-1.


Midgut microbiota affects the intestinal barrier by producing short-chain fatty acids in .

Song M, Zhang Z, Li Y, Xiang Y, Li C Front Microbiol. 2023; 14:1263731.

PMID: 37915855 PMC: 10616862. DOI: 10.3389/fmicb.2023.1263731.


GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP.

Heo Y, Yang E, Lee Y, Seo Y, Ryu K, Jeon H Int J Mol Sci. 2022; 23(18).

PMID: 36142527 PMC: 9506296. DOI: 10.3390/ijms231810631.


Claudin-1 Mediated Tight Junction Dysfunction as a Contributor to Atopic March.

Xia Y, Cao H, Zheng J, Chen L Front Immunol. 2022; 13:927465.

PMID: 35844593 PMC: 9277052. DOI: 10.3389/fimmu.2022.927465.


References
1.
Roche N, Stirling R, Lim S, Oliver B, Oates T, Jazrawi E . Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 in alveolar macrophages. J Allergy Clin Immunol. 2003; 111(2):367-73. DOI: 10.1067/mai.2003.6. View

2.
Palmer C, Irvine A, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee S . Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38(4):441-6. DOI: 10.1038/ng1767. View

3.
Kauffman H . Innate immune responses to environmental allergens. Clin Rev Allergy Immunol. 2006; 30(2):129-40. DOI: 10.1385/criai:30:2:129. View

4.
Jahnsen F, Strickland D, Thomas J, Tobagus I, Napoli S, Zosky G . Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus. J Immunol. 2006; 177(9):5861-7. DOI: 10.4049/jimmunol.177.9.5861. View

5.
Ying S, Meng Q, Corrigan C, Lee T . Lack of filaggrin expression in the human bronchial mucosa. J Allergy Clin Immunol. 2006; 118(6):1386-8. DOI: 10.1016/j.jaci.2006.08.030. View